Pharmaceutical News

RSS

NIH boosts funding for first large-scale clinical trial aimed at identifying drugs for Alzheimer's

The National Institutes of Health has boosted funding for the first large-scale clinical trial aimed at identifying drugs to stop or slow Alzheimer's disease in people destined to get the debilitating illness.

6 Nov 2014

Impax announces submission of EMA Marketing Authorization Application for IPX066

Impax Laboratories (Netherlands) B.V., a wholly owned subsidiary of Impax Laboratories, Inc. today announced that it has submitted a Marketing Authorization Application for IPX066 to the European Medicines Agency. IPX066 is an investigational extended-release capsule formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson's disease.

6 Nov 2014

Acino recognized with 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership

Based on its recent analysis of the pharmaceutical drug delivery industry, Frost & Sullivan recognizes Acino Pharma AG with the 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership. Acino's expertise in targeted drug release profiles and strong technical know-how in pellet-coating, transdermal therapeutic patches and biodegradable implants has made it the preferred vendor in contract manufacturing.

6 Nov 2014

Perrigo re-launches shipments of Guaifenesin 600mg Extended-Release tablets

Perrigo Company plc announced today that it has reinitiated shipments of Guaifenesin 600mg Extended-Release tablets to its retail and wholesale customers in the United States. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex 600mg Extended-Release tablets.

6 Nov 2014

AZD3965 drug inhibits growth of tumours in the lab

Manchester scientists have shown that a new drug inhibits the growth of tumours in the lab and that its effectiveness is improved by combining it with radiotherapy - suggesting a new approach that could be used in the clinic.

6 Nov 2014

Murdoch University researchers receive NHMRC grant to develop genetic drugs for rare diseases

Murdoch University researchers from the Centre for Comparative Genomics have received almost $800,000 in funding from the National Health and Medical Research Council to develop genetic drugs to treat rare diseases.

6 Nov 2014

Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

Introducing competing "biosimilar" versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the United States by $44 billion over the next decade, according to new analysis from the RAND Corporation.

6 Nov 2014

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

5 Nov 2014

Commonly prescribed drugs for arthritis and pain may increase risk of death from stroke

Commonly prescribed, older drugs for arthritis and pain may increase the risk of death from stroke, according to a study published in the November 5, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. Stroke is the fourth leading cause of death in the United States, according to the Centers for Disease Control and Prevention.

5 Nov 2014

Hospira launches Paricalcitol Injection

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced the launch of Paricalcitol Injection, a generic version of AbbVie's Zemplar. Hospira obtained U.S. Food and Drug Administration approval of paricalcitol on Oct. 21 and launched the product Nov. 1.

5 Nov 2014

ProstaCaid dietary supplement supports prostate health

A recent presentation at an international cancer research conference in Greece reviewed the body of data on ProstaCaid, a dietary supplement compound for prostate health. A number of published studies demonstrate the formula's effects in supporting prostate health against specific prostate cancer cell lines and prostate urinary symptoms.

5 Nov 2014

Dietary supplement KoACT is superior to calcium, vitamin D for bone health, study reveals

A new study by a Florida State University researcher reveals that a new dietary supplement is superior to calcium and vitamin D when it comes to bone health.

5 Nov 2014

Ranbaxy obtains FDA approval to manufacture, market Fenofibrate Capsules USP, 43 mg and 130 mg

Ranbaxy Laboratories Limited announced today that the Company has received approval from the U.S. Food and Drug Administration to manufacture and market Fenofibrate Capsules USP, 43 mg and 130 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Antara Capsules, 43 and 130 mg, respectively, of Lupin Atlantis.

5 Nov 2014

Non-injectable vaccine may provide long-term protection against deadly Ebola virus

A potentially breathable, respiratory vaccine in development has been shown to provide long-term protection for non-human primates against the deadly Ebola virus, as reported this week in the online edition of the journal Molecular Pharmaceutics.

5 Nov 2014

BioElectronics to present innovative chronic pain therapy at OTC Pharma Asia Conference

BioElectronics Corporation, the maker of advanced consumer and healthcare medical devices announced today that its Executive Vice President, Dr. Deepak Kotak has been invited to present BioElectronics' innovative chronic pain therapy at the OTC Pharma Asia Conference, on Tuesday, March 3, 2015 in Singapore.

5 Nov 2014

Mylan announces U.S. launch of generic Loestrin 24 Fe

Mylan Inc. today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of Warner Chilcott's Loestrin 24 Fe.

5 Nov 2014

Even brief workouts can reduce risk of relapse during meth withdrawal

Scientists at The Scripps Research Institute (TSRI) have found that even brief workouts can reduce the risk of relapse in rats withdrawing from methamphetamine. In addition, the team found that exercise affected the neurons in a brain region that had never before been associated with meth withdrawal, suggesting a new direction for drug development.

5 Nov 2014

Glenmark gets final approval from FDA for Omeprazole DR Capsules ANDA

Glenmark Generics Inc. USA, the subsidiary of Glenmark Generics Limited, has been granted final approval for its abbreviated new drug application (ANDA) from the United States Food and Drug Administration for Omeprazole Delayed Release Capsules, their generic version of Prilosec by AstraZeneca.

5 Nov 2014

Researchers develop new test to identify drugs that could work against Lyme disease

Researchers from the Johns Hopkins Bloomberg School of Public Health have developed a test they say will allow them to test thousands of FDA-approved drugs to see if they will work against the bacteria that causes tick-borne Lyme disease.

4 Nov 2014

Hemp Health launches CBD wellness supplements

Hemp Health Inc., a pioneer in hemp cannabidiol (CBD) products, today launched their line of CBD wellness supplements. Available in oil, spray and capsule form, Hemp Health's products offer a compelling alternative to medical marijuana. The CBD supplements provide consumers with the therapeutic ingredient in hemp while allowing them to avoid the negative mental and physical effects of marijuana.

4 Nov 2014

Pharmaceutical News

NIH boosts funding for first large-scale clinical trial aimed at identifying drugs for Alzheimer's

Impax announces submission of EMA Marketing Authorization Application for IPX066

Acino recognized with 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership

Perrigo re-launches shipments of Guaifenesin 600mg Extended-Release tablets

AZD3965 drug inhibits growth of tumours in the lab

Murdoch University researchers receive NHMRC grant to develop genetic drugs for rare diseases

Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Commonly prescribed drugs for arthritis and pain may increase risk of death from stroke

Hospira launches Paricalcitol Injection

ProstaCaid dietary supplement supports prostate health

Dietary supplement KoACT is superior to calcium, vitamin D for bone health, study reveals

Ranbaxy obtains FDA approval to manufacture, market Fenofibrate Capsules USP, 43 mg and 130 mg

Non-injectable vaccine may provide long-term protection against deadly Ebola virus

BioElectronics to present innovative chronic pain therapy at OTC Pharma Asia Conference

Mylan announces U.S. launch of generic Loestrin 24 Fe

Even brief workouts can reduce risk of relapse during meth withdrawal

Glenmark gets final approval from FDA for Omeprazole DR Capsules ANDA

Researchers develop new test to identify drugs that could work against Lyme disease

Hemp Health launches CBD wellness supplements

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News